Literature DB >> 8758261

Sensitivity of testis tumour cells to chemotherapeutic drugs: role of detoxifying pathways.

J R Masters1, R Thomas, A G Hall, L Hogarth, E C Matheson, A R Cattan, H Lohrer.   

Abstract

In contrast to most other types of cancer, metastatic testicular germ cell tumours (TGCT) are cured in most patients using cisplatin-based combination chemotherapy. The biochemical mechanisms underlying this sensitivity have not been defined. Drug detoxification can modulate response to chemotherapy in vivo and in vitro, and therefore we measured levels of glutathione (GSH), glutathione-S-transferase (GST) and both constitutive and cisplatin- and dexamethasone-induced levels of metallothionein (MT) in five human testis tumour cell lines. The levels were compared with those in five human bladder cancer cell lines and two cell lines with cisplatin resistance acquired in vitro. GSH levels were relatively low in the testis tumour cell lines, as might be expected in drug-sensitive cells, and there was a 77-fold increase in GSH levels in the cisplatin-resistant testis tumour cell line. GST levels were similar in the two cell types, while metallothionein levels were relatively high in the testis tumour cell lines. These data indicate that GSH may contribute to the sensitivity of TGCT to chemotherapy, and that GSH expression may be involved in the acquisition of cisplatin resistance in these tumours.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8758261     DOI: 10.1016/0959-8049(96)00033-0

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  14 in total

Review 1.  Novel molecular targets for urothelial carcinoma.

Authors:  Bishoy M Faltas; Beerinder S Karir; Scott T Tagawa; Jonathan E Rosenberg
Journal:  Expert Opin Ther Targets       Date:  2015-01-30       Impact factor: 6.902

2.  Molecular genetics of testicular germ cell tumors.

Authors:  Yuri Sheikine; Elizabeth Genega; Jonathan Melamed; Peng Lee; Victor E Reuter; Huihui Ye
Journal:  Am J Cancer Res       Date:  2012-02-15       Impact factor: 6.166

3.  Testicular Germ Cell Tumors: A Paradigm for the Successful Treatment of Solid Tumor Stem Cells.

Authors:  Caryl J Giuliano; Sarah J Freemantle; Michael J Spinella
Journal:  Curr Cancer Ther Rev       Date:  2006-08-01

4.  Cloning and characterization of the human glutathione synthetase 5'-flanking region.

Authors:  Taunia D Lee; Heping Yang; Janet Whang; Shelly C Lu
Journal:  Biochem J       Date:  2005-09-01       Impact factor: 3.857

Review 5.  Molecular mechanisms behind the resistance of cisplatin in germ cell tumours.

Authors:  Josep Ma Piulats; Laura Jiménez; Xavier García del Muro; Alberto Villanueva; Francesc Viñals; José R Germà-Lluch
Journal:  Clin Transl Oncol       Date:  2009-12       Impact factor: 3.405

6.  Anti-tumour activity of two novel compounds in cisplatin-resistant testicular germ cell cancer.

Authors:  B Nitzsche; C Gloesenkamp; M Schrader; B Hoffmann; F Zengerling; S Balabanov; F Honecker; M Höpfner
Journal:  Br J Cancer       Date:  2012-11-20       Impact factor: 7.640

7.  p53 hypersensitivity is the predominant mechanism of the unique responsiveness of testicular germ cell tumor (TGCT) cells to cisplatin.

Authors:  Matthias Gutekunst; Moshe Oren; Andrea Weilbacher; Michael A Dengler; Christiane Markwardt; Jürgen Thomale; Walter E Aulitzky; Heiko van der Kuip
Journal:  PLoS One       Date:  2011-04-21       Impact factor: 3.240

8.  Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to Cisplatin and poly (adp-ribose) polymerase inhibition.

Authors:  Francesca Cavallo; Grazia Graziani; Cristina Antinozzi; Darren R Feldman; Jane Houldsworth; George J Bosl; Raju S K Chaganti; Mary Ellen Moynahan; Maria Jasin; Marco Barchi
Journal:  PLoS One       Date:  2012-12-12       Impact factor: 3.240

9.  Association of metallothionein expression and clinical response to cisplatin based chemotherapy in testicular germ cell tumors.

Authors:  Emre Tuzel; Kutsal Yorukoglu; Esra Ozkara; Ziya Kirkali
Journal:  Cent European J Urol       Date:  2015-03-13

10.  Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11.

Authors:  Ross M Drayton; Ewa Dudziec; Stefan Peter; Simone Bertz; Arndt Hartmann; Helen E Bryant; James Wf Catto
Journal:  Clin Cancer Res       Date:  2014-02-10       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.